Nutriband Showcases AVERSA™ Abuse-Deterrent Technology Addressing Opioid Crisis at Emerging Growth Conference
Nutriband Inc. presented its AVERSA™ abuse-deterrent transdermal technology at the August 2025 Emerging Growth Conference, projecting peak annual sales of $200 million for its fentanyl patch upon FDA approval with potential to exceed $800 million, offering a critical solution to the ongoing opioid epidemic.
Nutriband Inc. (NASDAQ: NTRB) founder and president Serguei Melnik presented the company's AVERSA™ abuse-deterrent transdermal technology at the August 2025 Emerging Growth Conference, highlighting its potential to address the ongoing opioid crisis. The proprietary technology integrates aversive agents to prevent misuse, abuse, and accidental exposure of drugs with high abuse potential, particularly opioids.
The AVERSA™ platform represents a significant advancement in transdermal drug delivery, transforming traditional patches into safer tools for patients requiring powerful pain relief while reducing risks that have contributed to the national epidemic. With the opioid crisis continuing to underscore the urgent need for more secure drug delivery methods, Nutriband positions itself as a company offering a tangible solution through its innovative technology.
Financial projections indicate substantial market potential for the technology. AVERSA™ fentanyl is projected to achieve peak annual sales of $200 million upon FDA approval, with upside potential exceeding $800 million. This revenue projection reflects both the market need for safer opioid delivery systems and the commercial viability of Nutriband's approach to addressing public health concerns.
Nutriband's corporate structure differs from many biotechnology companies, as it sustains itself through multiple revenue-generating subsidiaries rather than relying solely on investor capital. The company, founded in 2016, completed its initial public offering in 2021 and has continued to develop its abuse-deterrent technology platform. Additional information about the company's developments is available through its newsroom at https://ibn.fm/NTRB.
The presentation at the Emerging Growth Conference emphasized how AVERSA™ technology could help mitigate the risks associated with transdermal opioid delivery while maintaining therapeutic efficacy for legitimate patients. By incorporating aversive agents that activate when the patch is manipulated or misused, the technology provides an additional layer of protection against abuse while preserving the intended medical benefits for appropriate use.